2008
DOI: 10.1002/ccd.21831
|View full text |Cite
|
Sign up to set email alerts
|

Amplatzer occlusion of accessory ventriculopulmonary connections

Abstract: Amplatzer occlusion devices provide a safe and effective means of eliminating accessory ventriculopulmonary connections in children who have undergone surgical palliation of congenital heart disease.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
7
0

Year Published

2010
2010
2019
2019

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 11 publications
(7 citation statements)
references
References 10 publications
0
7
0
Order By: Relevance
“…The FDA approved the amplatzer vascular plug 1 and 2 for use in May 2004, and September 2007, respectively. Since that time, there have been numerous published reports describing their utility for vascular occlusion procedures in a variety of clinical settings, including the peripheral vasculature [3], pulmonary AVMs [11–13], venous collaterals [14], aorto‐pulmonary collaterals [15], coronary fistulae [16–18], patent ductus ateriosus [7, 19], modified Blalock‐Taussig shunts [20], Fontan fenestrations [21], ventriculo‐pulmonary connections [22], vena cava aneurysms [23], perivalvular leaks [24], and porto‐systemic connections [9, 25]. The majority of these reports are small series that describe the original plug 1 device, with few reports describing plug 2 [4–6].…”
Section: Discussionmentioning
confidence: 99%
“…The FDA approved the amplatzer vascular plug 1 and 2 for use in May 2004, and September 2007, respectively. Since that time, there have been numerous published reports describing their utility for vascular occlusion procedures in a variety of clinical settings, including the peripheral vasculature [3], pulmonary AVMs [11–13], venous collaterals [14], aorto‐pulmonary collaterals [15], coronary fistulae [16–18], patent ductus ateriosus [7, 19], modified Blalock‐Taussig shunts [20], Fontan fenestrations [21], ventriculo‐pulmonary connections [22], vena cava aneurysms [23], perivalvular leaks [24], and porto‐systemic connections [9, 25]. The majority of these reports are small series that describe the original plug 1 device, with few reports describing plug 2 [4–6].…”
Section: Discussionmentioning
confidence: 99%
“…If there is a wide space on both sides of the pulmonary valve in patients with native pulmonary artery stenosis, the chosen device should have a retention disk on both sides, such as a septal occluder. [7,11] Petko et al [11] used an ASO, Ductal Occluder and AVP, while Desai et al [8] preferred a Rashkind Umbrella Occluder, Amplatzer Septal and Ductal Occluder, and Shanghai Shape Memory Alloy (SHSMA) muscular ventricular septal defect occluder (Shanghai Shape Memory Alloy Co., Ltd. Shanghai, China) device was deployed at the ligation site of pulmonary trunk for APF occlusion by Li et al [12] The aforementioned studies all reported successful results. In our study, we used an ASO in four patients and an AVP-II in two patients.…”
Section: Discussionmentioning
confidence: 99%
“…Since those diseases which need Fontan surgery are complicated, the following treatments are variable. Therefore the route of transcatheter catheterization after such surgeries is meaningful [2,3]. In this case, the residual ventriculopulmonary blood flow which was not completely certain under echocardiography increased the pulmonary blood flow and then the pressure which made the subtle Fontan circulation unbalanced and thus, resulted in the repeated edema and pleural effusion.…”
Section: Contents Lists Available At Sciencedirectmentioning
confidence: 99%
“…Many patients with Fontan circulation enjoy a high quality of life; however, there are still some complications [1]. Among them, the residual ventriculopulmonary blood flow after ligation of pulmonary trunk is very rare [2,3]. And the dispose of this residual shunt is meaningful.…”
mentioning
confidence: 99%